Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating ...

CompanyOverview|NASDAQ:GILD] Gilead Sciences Inc. (NASDAQ: GILD) stock surged to a new 52-week high at $106.69 recently on ...

The EMA is set to perform accelerated reviews of Gilead Sciences’ applications for its twice-yearly injectable for HIV ...

We recently published a list of Renaissance Technologies Portfolio: Top 10 Stock Picks. In this article, we are going to take ...

The S&P500 (SP500) closed in the red on Friday, after the week saw dour economic reports, headlines on U.S. President Donald ...

Gilead Sciences has announced that the US Food and Drug Administration (FDA) has accepted its New Drug Application ...

Shares of Gilead Sciences ( GILD -1.77%) were jumping 7.9% higher on Wednesday at 11:34 a.m. The solid gain came after the ...

Gilead Sciences posted fourth-quarter results that exceeded Wall Street estimates on Tuesday as its HIV drug sales rose 16% ...

Gilead Sciences reported strong fourth-quarter earnings with significant growth in its HIV and oncology segments.

Gilead Sciences Inc. closed 1.35% below its 52-week high of $106.69, which the company achieved on February 14th.

At the State of Black Health second annual summit hosted by BlackDoctor.org in partnership with USA TODAY, corporate leaders ...